Increased tuberculosis patient mortality associated with Mycobacterium tuberculosis mutations conferring resistance to second-line antituberculous drugs

Journal of Clinical Microbiology

Volumn 55, Issue 6, 2017, Pages 1928-1937

  Georghiou, Sophia B ^a   Seifert, Marva ^b   Catanzaro, Donald G ^c   Garfein, Richard S ^b   Rodwell, Timothy C ^b  

^a FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF ARKANSAS   (United States)

Author keywords

Diagnostics; Molecular genetics; Multidrug resistance; Mycobacterium tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GENE MUTATION; GYRA GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK FACTOR; RRS GENE; SMOKING; TUBERCULOSIS; ADOLESCENT; AGED; CHILD; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MUTATION; RISK ASSESSMENT; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; CHILD; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RISK ASSESSMENT; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85019633645     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00152-17     Document Type: Article

References (40)

1. Kambli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udwadia Z, Georghiou SG, Rodwell TC, Catanzaro A, Rodrigues C. 2016. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. Int J Mycobacteriol 5:1-6. https://doi.org/10.1016/j.ijmyco.2015.09.001.
2. Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro C, Rodrigues C. 2015. Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations. Diagn Microbiol Infect Dis 82:49-53. https://doi.org/10.1016/j.diagmicrobio.2015.01.009.
3. Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, Rodwell TC, Catanzaro A, Rodrigues C. 2015. Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis 95:137-141. https://doi.org/10.1016/j.tube.2014.11.003.
4. Zaunbrecher MA, Sikes RD, Jr, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106:20004-20009. https://doi.org/10.1073/pnas.0907925106.
5. Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. 2014. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 52:2157-2162. https://doi.org/10.1128/JCM.00691-14.
6. Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A. 2016. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother 71:314-323. https://doi.org/10.1093/jac/dkv360.
7. Huyen MN, Cobelens FG, Buu TN, Lan NT, Dung NH, Kremer K, Tiemersma EW, van Soolingen D. 2013. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 57:3620-3627. https://doi.org/10.1128/AAC.00077-13.
8. Leung KL, Yip CW, Yeung YL, Wong KL, Chan WY, Chan MY, Kam KM. 2010. Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. J Appl Microbiol 109:2087-2094. https://doi.org/10.1111/j.1365-2672.2010.04840.x.
9. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, Lewis CA, Freeman JT. 2012. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 16:216-220. https://doi.org/10.5588/ijtld.11.0178.
10. Shah NS, Grace Lin SY, Barry PM, Cheng YN, Schecter G, Desmond E. 2016. Clinical impact on tuberculosis treatment outcomes of discordance between molecular and growth-based assays for rifampin resistance, California 2003-2013. Open Forum Infect Dis 3:ofw150. https://doi.org/10.1093/ofid/ofw150.
11. Catanzaro A, Rodwell T, Catanzaro D, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N, Crudu V, Victor TC, Rodrigues C, Lin GS, Valafar F, Desmond E, Eisenach K. 2015. Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis. PLoS One 10:e0136861. https://doi.org/10.1371/journal.pone.0136861.
12. Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin SY, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A. 2014. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 15:434. https://doi.org/10.1186/1745-6215-15-434.
13. Sowajassatakul A, Prammananan T, Chaiprasert A, Phunpruch S. 2014. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiol 14:165. https://doi.org/10.1186/1471-2180-14-165.
14. Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17:1128-1134. https://doi.org/10.1111/j.1469-0691.2011.03551.x.
15. World Health Organization. 2012. Updated interim critical concentrations for first-line and second-line DST. http://www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table-1st%20and%202nd%20line%20drugs.pdf.
16. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H. 2010. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi region in India. Antimicrob Agents Chemother 54:4789-4793. https://doi.org/10.1128/AAC.00661-10.
17. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 67:1088-1093. https://doi.org/10.1093/jac/dks033.
18. Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, de Jong BC. 2015. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 19:185-190. https://doi.org/10.5588/ijtld.14.0651.
19. Ho J, Jelfs P, Sintchencko V. 2013. Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J Antimicrob Chemother 68:2915-2920. https://doi.org/10.1093/jac/dkt284.
20. van Ingen J, Aarnoutse R, de Vries G, Boeree MJ, van Soolingen D. 2011. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 15:990-992. https://doi.org/10.5588/ijtld.10.0127.
21. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. 2011. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 53:369-372. https://doi.org/10.1093/cid/cir406.
22. Dantes R, Metcalfe J, Kim E, Kato-Maeda M, Hopewell PC, Kawamura M, Nahid P, Cattamanchi A. 2012. Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. PLoS One 7:e37956. https://doi.org/10.1371/journal.pone.0037956.
23. Torres JN, Paul LV, Rodwell TC, Victor TC, Amallraja AM, Elghraoui A, Goodmanson AP, Ramirez-Busby SM, Chawla A, Zadorozhny M, Sirgel FA, Catanzaro D, Rodrigues C, Gler MT, Crudu V, Catanzaro A, Valafar F. 2015. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect 4:e42. https://doi.org/10.1038/emi.2015.42.
24. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. https://doi.org/10.1371/journal.pone.0033275.
25. Lin SY, Desmond E, Bonato D, Gross W, Siddiqi S. 2009. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 47:3630-3634. https://doi.org/10.1128/JCM.00803-09.
26. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 12:1449-1455.
27. Siddiqi S. 2006. MGIT procedure manual for Bactec MGIT 960 TB system. FIND Diagnostics. http://www.finddx.org/wp-content/uploads/2016/02/mgit-manual-nov2006.pdf.
28. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. http://www.who.int/tb/publications/2008/whohtmtb-2008-392/en/.
29. Lin SY, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond EP. 2014. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 52:475-482. https://doi.org/10.1128/JCM.01821-13.
30. Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC. 2016. Frequency and distribution of tuberculosis resistance-associated mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother 60:3994-4004. https://doi.org/10.1128/AAC.00222-16.
31. Dalla Costa ER, Ribeiro MO, Silva MS, Arnold LS, Rostirolla DC, Cafrune PI, Espinoza RC, Palaci M, Telles MA, Ritacco V, Suffys PN, Lopes ML, Campelo CL, Miranda SS, Kremer K, da Silva PE, Fonseca LDS, Ho JL, Kritski AL, Rossetti ML. 2009. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol 9:39. https://doi.org/10.1186/1471-2180-9-39.
32. Silva MS, Senna SG, Ribeiro MO, Valim AR, Telles MA, Kritski A, Morlock GP, Cooksey RC, Zaha A, Rossetti ML. 2003. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 41:4471-4474. https://doi.org/10.1128/JCM.41.9.4471-4474.2003.
33. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. 2006. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 55:1527-1531. https://doi.org/10.1099/jmm.0.46718-0.
34. Heym B, Honore N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs WR, Jr, van Embden JD, Grosset JH, Cole ST. 1994. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344:293-298. https://doi.org/10.1016/S0140-6736(94)91338-2.
35. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:2066-2069.
36. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. 2014. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 58:364-369. https://doi.org/10.1128/AAC.01228-13.
37. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. 2009. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 80:634-639.
38. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. 2001. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 32:623-632. https://doi.org/10.1086/318706.
39. Teale C, Goldman JM, Pearson SB. 1993. The association of age with the presentation and outcome of tuberculosis: a five-year survey. Age Ageing 22:289-293. https://doi.org/10.1093/ageing/22.4.289.
40. Gajalakshmi V, Peto R, Kanaka TS, Jha P. 2003. Smoking and mortality from tuberculosis and other disease in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet 362:507-515. https://doi.org/10.1016/S0140-6736(03)14109-8.